Covid 19 Research using Clinical Trials (Home Page)
MethylprednisoloneWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (16)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug401 | Hydroxychloroquine, Doxycycline Wiki | 0.35 |
| drug399 | Hydroxychloroquine, Clindamycin, Primaquine - high dose. Wiki | 0.35 |
| drug430 | Interferon-Alpha2B Wiki | 0.35 |
| drug400 | Hydroxychloroquine, Clindamycin, Primaquine - low dose. Wiki | 0.35 |
| drug210 | ColdZyme® mouth spray Wiki | 0.35 |
| drug228 | Convalescent Serum Wiki | 0.35 |
| drug825 | Telephone survey Wiki | 0.35 |
| drug397 | Hydroxychloroquine, Azithromycin Wiki | 0.35 |
| drug818 | Tacrolimus Wiki | 0.35 |
| drug398 | Hydroxychloroquine, Clindamycin Wiki | 0.35 |
| drug748 | Siltuximab Wiki | 0.25 |
| drug1023 | standard care Wiki | 0.25 |
| drug854 | Tocilizumab Wiki | 0.18 |
| drug480 | Losartan Wiki | 0.13 |
| drug691 | Remdesivir Wiki | 0.11 |
| drug616 | Placebo Wiki | 0.04 |
Correlated MeSH Terms (9)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003139 | Common Cold NIH | 0.25 |
| D014947 | Wounds and Injuries NIH | 0.14 |
| D018450 | Disease Progression NIH | 0.13 |
| D011014 | Pneumonia NIH | 0.12 |
| D055370 | Lung Injury NIH | 0.11 |
| D013577 | Syndrome NIH | 0.05 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
| D018352 | Coronavirus Infections NIH | 0.02 |
There are 8 clinical trials
Clinical Trials
1 An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia
At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of different hormone doses in the treatment of 2019-nCoV severe Pneumonia.This study explores effective treatment programs for 2019-nCoV severe pneumonia and provides a reliable evidence-based basis for the treatment.
NCT04263402 2019-nCoV Severe Pneumonia Drug: Methylprednisolone Drug: Methylprednisolone MeSH:Pneumonia
HPO:Pneumonia
Primary Outcomes
Description: For mild patients: disease remission refers to relieved symptoms with improved lung CT; For severe patients: disease remission refers to relieved symptoms with improved lung CT; or SPO2>93% or PaO2/FiO2 >300mmHg.
Measure: Rate of disease remission Time: day 7
Description: the critical stage refers to respiratory failure that occurs and requires mechanical ventilation, shock, or having other organ failure that needs ICU monitoring and treatment.
Measure: Rate and time of entering the critical stage Time: day 7
Secondary Outcomes
Description: Rate of patients without fever at day 7
Measure: Rate of normal tempreture Time: day 7
Description: Rate of patients with respiratory symptom remission at day 7
Measure: Rate of respiratory symptom remission Time: day 7
Description: Rate of patients with lung imaging recovery at day 7
Measure: Rate of lung imaging recovery Time: day 7
Description: Rate of patients with laboratory indicator recovery at day 7
Measure: Rate of laboratory indicator recovery Time: day 7
Description: Rate of patients withundetectable viral RNA at day 7
Measure: Rate of undetectable viral RNA Time: day 7
2 An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia
Primary Outcomes
Description: For mild patients: disease remission refers to relieved symptoms with improved lung CT; For severe patients: disease remission refers to relieved symptoms with improved lung CT; or SPO2>93% or PaO2/FiO2 >300mmHg.
Measure: Rate of disease remission Time: day 7Description: the critical stage refers to respiratory failure that occurs and requires mechanical ventilation, shock, or having other organ failure that needs ICU monitoring and treatment.
Measure: Rate and time of entering the critical stage Time: day 7Secondary Outcomes
Description: Rate of patients without fever at day 7
Measure: Rate of normal tempreture Time: day 7Description: Rate of patients with respiratory symptom remission at day 7
Measure: Rate of respiratory symptom remission Time: day 7Description: Rate of patients with lung imaging recovery at day 7
Measure: Rate of lung imaging recovery Time: day 7Description: Rate of patients with laboratory indicator recovery at day 7
Measure: Rate of laboratory indicator recovery Time: day 7Description: Rate of patients withundetectable viral RNA at day 7
Measure: Rate of undetectable viral RNA Time: day 7At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of different hormone doses in the treatment of 2019-nCoV severe Pneumonia.This study explores effective treatment programs for 2019-nCoV severe pneumonia and provides a reliable evidence-based basis for the treatment.
NCT04263402 2019-nCoV Severe Pneumonia Drug: Methylprednisolone Drug: Methylprednisolone MeSH:Pneumonia
HPO:Pneumonia
Primary Outcomes
Description: For mild patients: disease remission refers to relieved symptoms with improved lung CT; For severe patients: disease remission refers to relieved symptoms with improved lung CT; or SPO2>93% or PaO2/FiO2 >300mmHg.
Measure: Rate of disease remission Time: day 7
Description: the critical stage refers to respiratory failure that occurs and requires mechanical ventilation, shock, or having other organ failure that needs ICU monitoring and treatment.
Measure: Rate and time of entering the critical stage Time: day 7
Secondary Outcomes
Description: Rate of patients without fever at day 7
Measure: Rate of normal tempreture Time: day 7
Description: Rate of patients with respiratory symptom remission at day 7
Measure: Rate of respiratory symptom remission Time: day 7
Description: Rate of patients with lung imaging recovery at day 7
Measure: Rate of lung imaging recovery Time: day 7
Description: Rate of patients with laboratory indicator recovery at day 7
Measure: Rate of laboratory indicator recovery Time: day 7
Description: Rate of patients withundetectable viral RNA at day 7
Measure: Rate of undetectable viral RNA Time: day 7
3 Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails
Primary Outcomes
Description: For mild patients: disease remission refers to relieved symptoms with improved lung CT; For severe patients: disease remission refers to relieved symptoms with improved lung CT; or SPO2>93% or PaO2/FiO2 >300mmHg.
Measure: Rate of disease remission Time: day 7Description: the critical stage refers to respiratory failure that occurs and requires mechanical ventilation, shock, or having other organ failure that needs ICU monitoring and treatment.
Measure: Rate and time of entering the critical stage Time: day 7Secondary Outcomes
Description: Rate of patients without fever at day 7
Measure: Rate of normal tempreture Time: day 7Description: Rate of patients with respiratory symptom remission at day 7
Measure: Rate of respiratory symptom remission Time: day 7Description: Rate of patients with lung imaging recovery at day 7
Measure: Rate of lung imaging recovery Time: day 7Description: Rate of patients with laboratory indicator recovery at day 7
Measure: Rate of laboratory indicator recovery Time: day 7Description: Rate of patients withundetectable viral RNA at day 7
Measure: Rate of undetectable viral RNA Time: day 7There is still controversy about the effective of glucocorticoids for the treatment of novel coronavirus pneumonia. This is a prospective randomized controlled trails. The aim is to explore the effectiveness and safety of glucocorticoids in the treatment of novel coronavirus pneumonia.
NCT04273321 COVID-19 Novel Coronavirus Pneumonia Drug: Methylprednisolone MeSH:Pneumonia
HPO:Pneumonia
Primary Outcomes
Description: The clinical symptoms and signs continue to deteriorate, or new pulmonary or extrapulmonary lesions appear, or the chest imaging indicates the progress, and the patient is transferred to ICU or intubation and invasive ventilation or died.
Measure: the incidence of treatment failure in 14 days Time: 14 days
Secondary Outcomes
Description: The clinical symptoms and signs improved or alleviated (the temperature be normal , respiratory symptoms improved significantly, imaging showed obvious absorption) and no additional or alternative treatment was needed.
Measure: clinical cure incidence in 14 days Time: 14 days
Description: the duration from admission to virus negative
Measure: the duration of virus change to negative Time: 30 days
Description: the patient die in 30 days
Measure: mortality at day 30 Time: 30 days
Description: the patients transform to ICU because of clinical deteriorate in 30 days
Measure: ICU admission rate in 30 days Time: 30 days
4 Prolonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome
Primary Outcomes
Description: The clinical symptoms and signs continue to deteriorate, or new pulmonary or extrapulmonary lesions appear, or the chest imaging indicates the progress, and the patient is transferred to ICU or intubation and invasive ventilation or died.
Measure: the incidence of treatment failure in 14 days Time: 14 daysSecondary Outcomes
Description: The clinical symptoms and signs improved or alleviated (the temperature be normal , respiratory symptoms improved significantly, imaging showed obvious absorption) and no additional or alternative treatment was needed.
Measure: clinical cure incidence in 14 days Time: 14 daysDescription: the duration from admission to virus negative
Measure: the duration of virus change to negative Time: 30 daysDescription: the patient die in 30 days
Measure: mortality at day 30 Time: 30 daysDescription: the patients transform to ICU because of clinical deteriorate in 30 days
Measure: ICU admission rate in 30 days Time: 30 daysCOVID-19 infection is overwhelming Italian healthcare. There is an urgent need for a solution to the lack of ICU beds and increasing deaths day after day. A recent retrospective Chinese paper (JAMA Intern Med, online March 13, 2020) showed impressive positive effect of methylprednisolone (MP) on survival of SARS-CoV-2 critically ill patients. We're routinely using MP for severe pneumonia-ARDS with acute respiratory failure with very good results. The main objective of this multi-centre observational trial is to evaluate the efficacy of low dose prolonged infusion of methylprednisolone (MP) for patients with severe acute respiratory syndrome.
NCT04323592 Severe Acute Respiratory Syndrome (SARS) Pneumonia Coronavirus Infections ARDS, Human Drug: Methylprednisolone Other: standard care MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia Respiratory Distress Syndrome, Adult Syndrome
HPO:Pneumonia
Primary Outcomes
Description: Death or ICU admission or Invasive mechanical ventilation (yes/not, at least one of three of the composite end-point)
Measure: Composite primary end-point Time: 28 days
Description: Yes/no
Measure: death Time: 28 days
Description: yes/no
Measure: Admission to ICU Time: 28 days
Description: yes/no
Measure: Endotracheal intubation (invasive mechanical ventilation) Time: 28 days
Secondary Outcomes
Description: mg/L
Measure: reduction of C-reactive protein or CRP Time: 14 days and 28 days
Description: number of days free from mechanical ventilation (invasive or not)
Measure: Reduction of mechanical ventilation Time: 28 days
5 Phase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia
Primary Outcomes
Description: Death or ICU admission or Invasive mechanical ventilation (yes/not, at least one of three of the composite end-point)
Measure: Composite primary end-point Time: 28 daysDescription: Yes/no
Measure: death Time: 28 daysDescription: yes/no
Measure: Admission to ICU Time: 28 daysDescription: yes/no
Measure: Endotracheal intubation (invasive mechanical ventilation) Time: 28 daysSecondary Outcomes
Description: mg/L
Measure: reduction of C-reactive protein or CRP Time: 14 days and 28 daysDescription: number of days free from mechanical ventilation (invasive or not)
Measure: Reduction of mechanical ventilation Time: 28 daysIn our center up to 25% of the hospitalized patients with COVID-19 progress and need an intensive care unit. It is urgent to find measures that can avoid this progression to severe stages of the disease. We hypothesize that the use of anti-inflammatory drugs used at the time they start hyperinflammation episodes could improve symptoms and prognosis of patients and prevent their progression sufficiently to avoid their need for be admitted to an Intensive Care Unit.
NCT04329650 COVID-19 Drug: Siltuximab Drug: Methylprednisolone MeSH:Pneumonia
HPO:Pneumonia
Primary Outcomes
Measure: Proportion of patients requiring ICU admission at any time within the study period. Time: 29 days
Secondary Outcomes
Measure: Days of stay in the ICU during the study period. Time: 29 days
Measure: Days until resolution of fever defined as body temperature (axillary ≤ 36.6 ° C, oral ≤ 37.2 ° C, or rectal or tympanic ≤ 37.8 ° C) for at least 48 hours, without administration of antipyretics or until hospital discharge. Time: 29 days
Measure: Proportion of patients with a worsening requirement of supplemental oxygen at 29 days. days. Time: 29 days
Measure: Days with hypoxemia (SpO2 <93% in ambient air or requiring oxygen supplemental or mechanical ventilation support) at 29 days. Time: 29 days
Measure: Proportion of patients using mechanical ventilation at 29 days. Time: 29 days
Measure: Days with use of mechanical ventilation at 29 days. Time: 29 days
Measure: Days until the start of use of mechanical ventilation, non-invasive ventilation or use of high flow nasal cannula (if the patient have not previously required these interventions at the inclusion of the study) at 29 days. Time: 29 days
Measure: Days of hospitalization among survivors at 29 days. Time: 29 days
Measure: Mortality rate from any cause at 29 days. Time: 29 days
Measure: Proportion of patients with serious adverse events at 29 days. Time: 29 days
Measure: Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic with grade 4 neutropenia (count neutrophil absolute <500 / mm3) at 29 days. Time: 29 days
Measure: Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic at 29 days. Time: 29 days
Measure: Proportion of patients with grade 2 or higher adverse reactions related to the infusion of the sudy treatments at 29 days. Time: 29 days
Measure: Proportion of patients with hypersensitivity reactions of grade 2 or higher related to the administration of the study treatments at 29 days. Time: 29 days
Measure: Proportion of patients with gastrointestinal perforation at 29 days. Time: 29 days
Measure: Proportion of patients with secondary severe infections confirmed by laboratory or worsening of existing infections at 29 days. Time: 29 days
Measure: Changes from baseline in plasma leukocyte levels at days 1, 3, 5, 7 and 9. Time: Days 1, 3, 5, 7 and 9
Measure: Changes from baseline in plasma hemoglobin levels at days 1, 3, 5, 7 and 9. Time: Days 1, 3, 5, 7 and 9
Measure: Changes from baseline in plasma platelet at days 1, 3, 5, 7 and 9. Time: Days 1, 3, 5, 7 and 9
Measure: Changes from baseline in plasma creatinine levels at days 1, 3, 5, 7 and 9. Time: Days 1, 3, 5, 7 and 9
Measure: Changes from baseline in plasma total bilirubin levels at days 1, 3, 5, 7 and 9. Time: Days 1, 3, 5, 7 and 9
Measure: Proportion of patients with ALT≥ 3 times ULN (for patients with initial values normal) or> 3 times ULN AND at least 2 times more than the initial value (for patients with abnormal initial values) at days 1, 3, 5, 7 and 9. Time: Days 1, 3, 5, 7 and 9
Measure: Changes from baseline in plasma biomarkers (PCR, lymphocytes, ferritin, d-dimer and LDH) at days 1, 3, 5, 7 and 9. Time: Days 1, 3, 5, 7 and 9
Measure: Changes from baseline in chest Rx at days 1, 3 and 5. Time: Days 1, 3 and 5
6 Open Randomized Single Centre Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With Severe Lung Injury Secondary to COVID-19
Primary Outcomes
Measure: Proportion of patients requiring ICU admission at any time within the study period. Time: 29 daysSecondary Outcomes
Measure: Days of stay in the ICU during the study period. Time: 29 daysMeasure: Days until resolution of fever defined as body temperature (axillary ≤ 36.6 ° C, oral ≤ 37.2 ° C, or rectal or tympanic ≤ 37.8 ° C) for at least 48 hours, without administration of antipyretics or until hospital discharge. Time: 29 days
Measure: Proportion of patients with a worsening requirement of supplemental oxygen at 29 days. days. Time: 29 days
Measure: Days with hypoxemia (SpO2 <93% in ambient air or requiring oxygen supplemental or mechanical ventilation support) at 29 days. Time: 29 days
Measure: Proportion of patients using mechanical ventilation at 29 days. Time: 29 days
Measure: Days with use of mechanical ventilation at 29 days. Time: 29 days
Measure: Days until the start of use of mechanical ventilation, non-invasive ventilation or use of high flow nasal cannula (if the patient have not previously required these interventions at the inclusion of the study) at 29 days. Time: 29 days
Measure: Days of hospitalization among survivors at 29 days. Time: 29 days
Measure: Mortality rate from any cause at 29 days. Time: 29 days
Measure: Proportion of patients with serious adverse events at 29 days. Time: 29 days
Measure: Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic with grade 4 neutropenia (count neutrophil absolute <500 / mm3) at 29 days. Time: 29 days
Measure: Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic at 29 days. Time: 29 days
Measure: Proportion of patients with grade 2 or higher adverse reactions related to the infusion of the sudy treatments at 29 days. Time: 29 days
Measure: Proportion of patients with hypersensitivity reactions of grade 2 or higher related to the administration of the study treatments at 29 days. Time: 29 days
Measure: Proportion of patients with gastrointestinal perforation at 29 days. Time: 29 days
Measure: Proportion of patients with secondary severe infections confirmed by laboratory or worsening of existing infections at 29 days. Time: 29 days
Measure: Changes from baseline in plasma leukocyte levels at days 1, 3, 5, 7 and 9. Time: Days 1, 3, 5, 7 and 9
Measure: Changes from baseline in plasma hemoglobin levels at days 1, 3, 5, 7 and 9. Time: Days 1, 3, 5, 7 and 9
Measure: Changes from baseline in plasma platelet at days 1, 3, 5, 7 and 9. Time: Days 1, 3, 5, 7 and 9
Measure: Changes from baseline in plasma creatinine levels at days 1, 3, 5, 7 and 9. Time: Days 1, 3, 5, 7 and 9
Measure: Changes from baseline in plasma total bilirubin levels at days 1, 3, 5, 7 and 9. Time: Days 1, 3, 5, 7 and 9
Measure: Proportion of patients with ALT≥ 3 times ULN (for patients with initial values normal) or> 3 times ULN AND at least 2 times more than the initial value (for patients with abnormal initial values) at days 1, 3, 5, 7 and 9. Time: Days 1, 3, 5, 7 and 9
Measure: Changes from baseline in plasma biomarkers (PCR, lymphocytes, ferritin, d-dimer and LDH) at days 1, 3, 5, 7 and 9. Time: Days 1, 3, 5, 7 and 9
Measure: Changes from baseline in chest Rx at days 1, 3 and 5. Time: Days 1, 3 and 5
The primary objective of the study is to evaluate the days until reaching clinical stability after starting randomization in hospitalized patients with elevated inflammatory parameters and severe COVID-19 lung injury.
NCT04341038 COVID-19 Lung Injury Drug: Tacrolimus Drug: Methylprednisolone MeSH:Lung Injury Wounds and Injuries
Primary Outcomes
Description: Assess the days until clinical stability is achieved after initiating randomization in hospitalized patients with elevated inflammatory parameters and severe COVID-19 lung injury. Clinical stability is defined if all the following criteria are met for 48 consecutive hours: Body temperature ≤ 37.0ºC; PaO2 / FiO2> 400 and / or SatO2 / FiO2> 300; Respiratory rate ≤ 24 rpm
Measure: Time to reach clinical stability Time: 28 daysSecondary Outcomes
Description: days
Measure: Time to reach an afebrile state for 48 hours. Time: 56 daysDescription: days
Measure: Time to reach PaO2 / FiO2> 400 and / or SatO2 / FiO2> 300 Time: 56 daysDescription: days
Measure: Time to reach FR ≤ 24 rpm for 48 hours Time: 56 daysDescription: days
Measure: Time to normalization of D-dimer (<250 ug / L) Time: 56 daysDescription: days
Measure: Time until PCR normalization (<5mg / L). Time: 56 daysDescription: days
Measure: Time until normalization of ferritin (<400ug / L) Time: 56 daysDescription: viral load
Measure: Study the impact of immunosuppressive treatment on viral load using quantitative PCR Time: 56 daysDescription: days
Measure: Time until hospital discharge Time: 56 daysDescription: days
Measure: Need for ventilatory support devices Time: 56 daysDescription: days
Measure: Duration that it is necessary to maintain ventilatory support. Time: 56 daysDescription: days
Measure: COVID-19 mortality Time: 56 daysDescription: days
Measure: all-cause mortality Time: 56 daysDescription: cytokines quantification technique by Luminex
Measure: Analyze the expanded cytokine profile before the start of treatment and their evolution every 7 days after admission Time: 56 daysDescription: IDIBELL Clinical Research and Clinical Trials Unit will oversee the monitoring and pharmacovigilance
Measure: Describe the side effects and their severity attributed to tacrolimus and / or methylprednisolone. Time: 56 days7 An Open-label, Randomized, Cross-over Interventional Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression
This study aims to compare the efficacy and safety of Methylprednisolone versus Tocilizumab in improving clinical outcomes and reducing the need for ventilator support in COVID-19 patients with moderate COVID-19 disease at risk for complications of cytokine storm. Approximately 310 participants hospitalized with COVID-19 in UMMC, Hospital Sungai Buloh, Hospital Kuala Lumpur and Hospital Tuanku Jaafar will be enrolled into this study. Eligible participants will be selected based on a set of clinical, laboratory and radiological parameters indicative of early stages of CRS and lung function decline prior to being randomized at a ratio of 1:1 to receive either Tocilizumab or Methylprednisolone. Participants will be monitored daily for clinical and laboratory parameters, and at 48 hours, switched to the alternate study arm should they manifest signs and symptoms indicative of decompensation.
NCT04345445 COVID-19 Drug: Tocilizumab Drug: Methylprednisolone MeSH:Disease Progression
Primary Outcomes
Measure: The proportion of patients requiring mechanical ventilation Time: Through study completion, and average of 6 monthsMeasure: Mean days of ventilation Time: Through study completion, and average of 6 months
Secondary Outcomes
Measure: The proportion of patients requiring ICU admission Time: Through study completion, and average of 6 monthsMeasure: Overall 28-day survival Time: 28 day from baseline
Measure: Change in symptom severity assessed by the World Health Organization (WHO) Coronavirus Disease 2019 (COVID19) ordinal scale measured daily up to 7 days from baseline Time: 7 days from baseline
Measure: Duration of hospital and ICU stay Time: Through study completion, and average of 6 months
8 The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol
Diagnostic determination of disease and treatment responses has been limited to qualitative imaging, measurement of serum markers of disease, and sampling of tissue. In each of these instances, there is a built in error either due to sensitivity and specificity issues, clinician interpretation of results, or acceptance of the use of an indirect marker (blood test) of what is happening elsewhere in the body - at the tissue level. The Fleming Method for Tissue and Vascular Differentiation and Metabolism (FMTVDM) using same state single or sequential quantification comparisons [1] provides the first and only patented test (#9566037) - along with the associated submitted patent applications ruled to be covered under #9566037 - that quantitatively measures changes in tissue resulting from inter alia a disease process. This includes inter alia coronary artery disease (CAD), cancer and infectious/inflammatory processes including CoVid-19 pneumonia (CVP) resulting from the metabolic and regional blood flow differences (RBFDs) caused by these diseases. The purpose of this paper is to make clinicians and researchers aware of this proposed method for investigating the prevalence and severity of CVP - in addition to providing rapid determination of treatment response in each patient, directing treatment decisions; thereby reducing the loss of time, money, resources and patient lives.
NCT04349410 CoVid 19 Positive Drug: Hydroxychloroquine, Azithromycin Drug: Hydroxychloroquine, Doxycycline Drug: Hydroxychloroquine, Clindamycin Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose. Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose. Drug: Remdesivir Drug: Tocilizumab Drug: Methylprednisolone Drug: Interferon-Alpha2B Drug: Losartan Drug: Convalescent Serum
Primary Outcomes
Description: Measured improvement in tissue as measured using FMTVDM
Measure: Improvement in FMTVDM Measurement with nuclear imaging. Time: 72 hoursSecondary Outcomes
Description: Extubation
Measure: Ventilator status Time: 7 daysDescription: Self explanatory
Measure: Survival status Time: 30 days